🇺🇸 FDA
Pipeline program

Giapreza 2.5 mg/ml concentrate for solution for infusion, SODIUM CHLORIDE SOLUTION 0.9%

CRH07

Phase 3 small_molecule active

Quick answer

Giapreza 2.5 mg/ml concentrate for solution for infusion, SODIUM CHLORIDE SOLUTION 0.9% for refractory hypotension in distributive shock is a Phase 3 program (small_molecule) at PAION Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
PAION Pharma GmbH
Indication
refractory hypotension in distributive shock
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials